Liver cirrhosis

被引:1058
作者
Gines, Pere [1 ,2 ,3 ,4 ]
Krag, Aleksander [5 ,6 ]
Abraldes, Juan G. [7 ]
Sola, Elsa [1 ,2 ,8 ]
Fabrellas, Nuria [2 ,3 ,4 ]
Kamath, Patrick S. [9 ]
机构
[1] Hosp Clin Barcelona, Liver Unit, Barcelona 08036, Spain
[2] Univ Barcelona, Fac Med & Hlth Sci, Barcelona, Spain
[3] Inst Biomed Invest August Pi & Sunyer, Barcelona, Spain
[4] Hepat & Digest Dis Biomed Invest Ctr, Madrid, Spain
[5] Odense Univ Hosp, Dept Gastroenterol & Hepatol, Liver Res Ctr, Odense, Denmark
[6] Univ Southern Denmark, Inst Clin Res, Odense, Denmark
[7] Univ Alberta, Div Gastroenterol, Liver Unit, Edmonton, AB, Canada
[8] Stanford Univ, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA
[9] Mayo Clin, Coll Med & Sci, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
PORTAL-VEIN THROMBOSIS; ACUTE KIDNEY INJURY; TRANSIENT ELASTOGRAPHY; HEPATORENAL-SYNDROME; DIAGNOSTIC-CRITERIA; ALCOHOL-CONSUMPTION; REFRACTORY ASCITES; STRATIFYING RISK; NATURAL-HISTORY; GUT MICROBIOME;
D O I
10.1016/S0140-6736(21)01374-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C infection, autoimmune diseases, cholestatic diseases, and iron or copper overload. Cirrhosis develops after a long period of inflammation that results in replacement of the healthy liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension. The disease evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which often result in hospitalisation, impaired quality of life, and high mortality. Progressive portal hypertension, systemic inflammation, and liver failure drive disease outcomes. The management of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation can be required in some cases. In this Seminar, we discuss the disease burden, pathophysiology, and recommendations for the diagnosis and management of cirrhosis and its complications. Future challenges include better screening for early fibrosis or cirrhosis, early identification and reversal of causative factors, and prevention of complications.
引用
收藏
页码:1359 / 1376
页数:18
相关论文
共 149 条
[1]  
Abbafati C, 2020, LANCET, V396, P1204
[2]   Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis [J].
Abraldes, JG ;
Tarantino, I ;
Turnes, J ;
Garcia-Pagan, JC ;
Rodés, J ;
Bosch, J .
HEPATOLOGY, 2003, 37 (04) :902-908
[3]   Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis [J].
Abraldes, Juan G. ;
Villanueva, Candid ;
Aracil, Carles ;
Turnes, Juan ;
Hernandez-Guerra, Manuel ;
Genesca, Joan ;
Rodriguez, Manuel ;
Castellote, Jose ;
Carlos Garcia-Pagan, Juan ;
Torres, Ferran ;
Luis Calleja, Jose ;
Albillos, Agustin ;
Bosch, Jaime .
GASTROENTEROLOGY, 2016, 150 (05) :1160-+
[4]   A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease [J].
Abul-Husn, N. S. ;
Cheng, X. ;
Li, A. H. ;
Xin, Y. ;
Schurmann, C. ;
Stevis, P. ;
Liu, Y. ;
Kozlitina, J. ;
Stender, S. ;
Wood, G. C. ;
Stepanchick, A. N. ;
Still, M. D. ;
McCarthy, S. ;
O'Dushlaine, C. ;
Packer, J. S. ;
Balasubramanian, S. ;
Gosalia, N. ;
Esopi, D. ;
Kim, S. Y. ;
Mukherjee, S. ;
Lopez, A. E. ;
Fuller, E. D. ;
Penn, J. ;
Chu, X. ;
Luo, J. Z. ;
Mirshahi, U. L. ;
Carey, D. J. ;
Still, C. D. ;
Feldman, M. D. ;
Small, A. ;
Damrauer, S. M. ;
Rader, D. J. ;
Zambrowicz, B. ;
Olson, W. ;
Murphy, A. J. ;
Borecki, I. B. ;
Shuldiner, A. R. ;
Reid, J. G. ;
Overton, J. D. ;
Yancopoulos, G. D. ;
Hobbs, H. H. ;
Cohen, J. C. ;
Gottesman, O. ;
Teslovich, T. M. ;
Baras, A. ;
Mirshahi, T. ;
Gromada, J. ;
Dewey, F. E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1096-1106
[5]   Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease [J].
Acharya, Chathur ;
Bajaj, Jasmohan S. .
GASTROENTEROLOGY, 2021, 160 (02) :556-572
[6]   The gut-liver axis in liver disease: Pathophysiological basis for therapy [J].
Albillos, Agustin ;
de Gottardi, Andrea ;
Rescigno, Maria .
JOURNAL OF HEPATOLOGY, 2020, 72 (03) :558-577
[7]   Stratifying Risk in the Prevention of Recurrent Variceal Hemorrhage: Results of an Individual Patient Meta-Analysis [J].
Albillos, Agustin ;
Zamora, Javier ;
Martinez, Javier ;
Arroyo, David ;
Ahmad, Irfan ;
De-la-Pena, Joaquin ;
Garcia-Pagan, Juan-Carlos ;
Lo, Gin-Ho ;
Sarin, Shiv ;
Sharma, Barjesh ;
Abraldes, Juan G. ;
Bosch, Jaime ;
Garcia-Tsao, Guadalupe .
HEPATOLOGY, 2017, 66 (04) :1219-1231
[8]   Time Trends in the Health Care Burden and Mortality of Acute on Chronic Liver Failure in the United States [J].
Allen, Alina M. ;
Kim, W. Ray ;
Moriarty, James P. ;
Shah, Nilay D. ;
Larson, Joseph J. ;
Kamath, Patrick S. .
HEPATOLOGY, 2016, 64 (06) :2165-2172
[9]  
Amer Assoc Study Liver Dis, 2014, J HEPATOL, V61, P642, DOI 10.1016/j.jhep.2014.05.042
[10]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854